The new 2018 guideline, published in the official journal of the College of Family Physicians of Canada, suggests that clinicians could consider medical cannabinoids only for refractory neuropathic pain and refractory pain in palliative care, chemotherapy-induced nausea and vomiting, and spasticity in multiple sclerosis and spinal cord injury after reasonable trials of standard therapies have failed.